Metabolism of plasma cholesterol and lipoprotein parameters are related to a higher degree of insulin sensitivity in high HDL-C healthy normal weight subjects

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Leança, Camila C ^a   Nunes, Valéria S ^a   Panzoldo, Natália B ^b   Zago, Vanessa S ^b   Parra, Eliane S ^b   Cazita, Patrícia M ^a   Jauhiainen, Matti ^c   Passarelli, Marisa ^a   Nakandakare, Edna R ^a   de Faria, Eliana C ^b   Quintão, Eder C R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Cholesteryl ester transfer protein; HDL C concentration; Insulin resistance; Lecithin cholesterol acyl transferase; Lipoprotein lipases; Phospholipid transfer protein; Plasma cholesterol metabolism markers; Pre beta1 HDL

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; PRE BETA HIGH DENSITY LIPOPROTEIN; PRE BETA1 HIGH DENSITY LIPOPROTEIN; STEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INTESTINE ABSORPTION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; NORMAL HUMAN; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; BRAZIL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IDEAL BODY WEIGHT; INSULIN; INSULIN RESISTANCE; INTESTINAL ABSORPTION; LIPASE; LIPID METABOLISM; LIPID METABOLISM, INBORN ERRORS; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEINS; YOUNG ADULT;

EID: 84887978325     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-173     Document Type: Article

References (47)

1. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374. 10.1124/pr.58.3.1, 16968945.
2. Leança CC, Nunes VS, Nakandakare ER, de Faria EC, Quintao EC. Does plasma HDL-C concentration interact with whole-body cholesterol metabolism?. Nutr Metab Cardiovasc Dis 2013, 23:279-284. 10.1016/j.numecd.2012.12.003, 23333727.
3. von Eckardstein A, Sibler RA. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011, 22:26-32. 10.1097/MOL.0b013e3283412279, 21102330.
4. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135. 10.1056/NEJMoa1001689, 3030449, 21226578.
5. Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, Rye KA. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 2010, 30:1642-1648. 10.1161/ATVBAHA.110.207373, 20466975.
6. Koseki M, Matsuyama A, Nakatani K, Inagaki M, Nakaoka H, Kawase R, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Sandoval JC, Ohama T, Nakagawa-Toyama Y, Matsuura F, Nishida M, Ishigami M, Hirano K, Sakane N, Kumon Y, Suehiro T, Nakamura T, Shimomura I, Yamashita S. Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb 2009, 16:292-296. 10.5551/jat.E599, 19556721.
7. Vergeer M, Brunham LR, Koetsveld J, Kruit JK, Verchere CB, Kastelein JJ, Hayden MR, Stroes ES. Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 2010, 33:869-874. 10.2337/dc09-1562, 2845043, 20067955.
8. Villarreal-Molina MT, Flores-Dorantes MT, Arellano-Campos O, Villalobos-Comparan M, Rodríguez-Cruz M, Miliar-García A, Huertas-Vazquez A, Menjivar M, Romero-Hidalgo S, Wacher NH, Tusie-Luna MT, Cruz M, Aguilar-Salinas CA, Canizales-Quinteros S. Metabolic study group: association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population. Diabetes 2008, 57:509-513.
9. Saleheen D, Nazir A, Khanum S, Haider SR, Frossard PM. R1615P: a novel mutation in ABCA1 associated with low levels of HDL and type II diabetes mellitus. Int J Cardiol 2006, 110:259-260. 10.1016/j.ijcard.2005.06.059, 16055210.
10. Daimon M, Kido T, Baba M, Oizumi T, Jimbu Y, Kameda W, Yamaguchi H, Ohnuma H, Tominaga M, Muramatsu M, Kato T. Association of the ABCA1 gene polymorphisms with type 2 DM in a Japanese population. Biochem Biophys Res Commun 2005, 329:205-210. 10.1016/j.bbrc.2005.01.119, 15721294.
11. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007, 13:340-347. 10.1038/nm1546, 17322896.
12. Welch CL, Bretschger S, Latib N, Bezouevski M, Guo Y, Pleskac N, Liang CP, Barlow C, Dansky H, Breslow JL, Tall AR. Localization of atherosclerosis susceptibility loci to chromosomes 4 and 6 using the Ldlr knockout mouse model. Proc Natl Acad Sci U S A 2001, 98:7946-7956. 10.1073/pnas.141239098, 35448, 11438740.
13. Brunham LR, Kruit JK, Verchere CB, Hayden MR. Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 2008, 118:403-408. 10.1172/JCI33296, 2214697, 18246189.
14. Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, de Courten B, Forbes JM, Yap FY, Kaye DM, van Hall G, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009, 119:2103-2111. 10.1161/CIRCULATIONAHA.108.843219, 19349317.
15. Ståhlman M, Fagerberg B, Adiels M, Ekroos K, Chapman JM, Kontush A, Borén J. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: Impact on small HDL particles. Biochim Biophys Acta 2013, 1831:1609-1617. 10.1016/j.bbalip.2013.07.009, 23896361.
16. Coniglio RI, Meroño T, Montiel H, Malaspina MM, Salgueiro AM, Otero JC, Ferraris R, Schreier L, Brites F, Gómez Rosso L. HOMA-IR and non-HDL-C as predictors of high cholesteryl ester transfer protein activity in patients at risk for type 2 diabetes. Clin Biochem 2012, 45:566-570. 10.1016/j.clinbiochem.2012.02.005, 22366373.
17. Boronat M, Saavedra P, Pérez-Martín N, López-Madrazo MJ, Rodríguez-Pérez C, Nóvoa FJ. High levels of lipoprotein (a) are associated with a lower prevalence of diabetes with advancing age: results of a cross-sectional epidemiological survey in Gran Canaria, Spain. Cardiovasc Diabetol 2012, 11:81. 10.1186/1475-2840-11-81, 3441762, 22748161.
18. de Vries R, Kappelle PJ, Dallinga-Thie GM, Dullaart RP. Plasma phospholipid transfer protein activity is independently determined by obesity and insulin resistance in non-diabetic subjects. Atherosclerosis 2011, 217:253-259. 10.1016/j.atherosclerosis.2011.03.021, 21481395.
19. Assman G, Cullen P, Kannenberg F, Schulte H. Relationship between phytosterol levels and components of the metabolic syndrome in the PROCAM study. Eur J Cardiovasc Prev Rehabil 2007, 14:208-214. 10.1097/HJR.0b013e3280148201, 17446798.
20. Paramsothy P, Knopp RH, Kahn SE, Retzlaff BM, Fish B, Ma L, Ostlund RE. Plasma sterol evidence for decreased absorption and increased synthesis of cholesterol in insulin resistance and obesity. Am J Clin Nutr 2011, 94:1182-1188. 10.3945/ajcn.110.006668, 3192472, 21940599.
21. Simonen PP, Gylling HK, Miettinen TA. Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care 2002, 25:1511-1521. 10.2337/diacare.25.9.1511, 12196419.
22. Nunes VS, Leança CC, Panzoldo NB, Parra E, Cazita PM, Nakandakare ER, de Faria EC, Quintão EC. HDL-C concentration is related to markers of absorption and of cholesterol synthesis: Study in subjects with low vs. high HDL-C. Clin Chim Acta 2011, 412:176-180. 10.1016/j.cca.2010.09.039, 20932966.
23. Robciuc MR, Maranghi M, Lahikainen A, Rader D, Bensadoun A, Öörni K, Metso J, Minicocci I, Ciociola E, Ceci F, Montali A, Arca M, Ehnholm C, Jauhiainen M. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler Thromb Vasc Biol 2013, 33:1706-1713. 10.1161/ATVBAHA.113.301397, 23661675.
24. Huang Y, Li X, Wang M, Ning HAL, Li Y, Sun C. Lipoprotein lipase links vitamin D, insulin resistance, and type 2 diabetes: a cross-sectional epidemiological study. Cardiovasc Diabetol 2013, 12:17. 10.1186/1475-2840-12-17, 3570389, 23320821.
25. Duvillard L, Florentin E, Pont F, Petit JM, Baillot-Rudoni S, Penfornis A, Vergès B. Chronic hyperinsulinemia does not increase the production rate of high-density lipoprotein apolipoprotein AI: evidence from a kinetic study in patients with insulinoma. Arterioscler Thromb Vasc Biol 2013, 33:2460-2465. 10.1161/ATVBAHA.113.301597, 23908245.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
27. Miettinen TA. Gas-liquid chromatographic determination of fecal neutral sterols using a capillary column. Clin Chim Acta 1982, 124:245-248. 10.1016/0009-8981(82)90393-X, 7139944.
28. Dobiasova M, Stribrna J, Pritchard PH, Frohlich JJ. Cholesterol esterification rate in plasma depleted of very low and low density lipoproteins is controlled by the proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle-aged and septuagenarian men. J Lipid Res 1992, 33:1411-1418.
29. Jauhiainen M, Ehnholm C. Determination of human plasma phospholipid transfer protein mass and activity. Methods Enzymol 2005, 36:97-101.
30. Ehnholm C, Kuusi T. Preparation, characterization, and measurement of hepatic lipase. Methods Enzymol 1986, 129:716-738.
31. Dullaart RP, Perton F, Sluiter WJ, de Vries R, van Tol A. Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J Clin Endocrinol Metab 2008, 93:4860-4866. 10.1210/jc.2008-1213, 18782872.
32. Li L, Hossain MA, Sadat S, Hager L, Liu L, Tam L, Schroer S, Huogen L, Fantus IG, Connelly PW, Woo M, Ng DS. Lecithin cholesterol acyltransferase null mice are protected from diet-induced obesity and insulin resistance in a gender-specific manner through multiple pathways. J Biol Chem 2011, 286:17809-17820. 10.1074/jbc.M110.180893, 3093856, 21454561.
33. Huttunen JK, Ehnholm C, Kekki M, Nikkilä EA. Post-heparin plasma lipoprotein lipase and hepatic lipase in normal subjects and in patients with hypertriglyceridaemia: correlations to sex, age and various parameters of triglyceride metabolism. Clin Sci Mol Med 1976, 50:249-260.
34. Povel CM, Boer JM, Feskens EJ. Shared genetic variance between the features of the metabolic syndrome: Heritability studies. Mol Genet Metab 2011, 104:666-689. 10.1016/j.ymgme.2011.08.035, 21963081.
35. Eriksson JW, Burén J, Svensson M, Olivecrona T, Olivecrona G. Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type 2 diabetes patients and healthy control subjects. Atherosclerosis 2003, 166:359-367. 10.1016/S0021-9150(02)00366-0, 12535750.
36. Salah A, Khan M, Esmail N, Habibullah S, Al Lahham Y. Genetic polymorphism of S447X lipoprotein lipase (LPL) and the susceptibility to hypertension. J Crit Care 2009, 24:e11-e14. 10.1016/j.jcrc.2009.06.005, 19664517.
37. Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Feskens EJ, Jansen EH, Schalkwijk CG, Stehouwer C. The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study). Metabolism 2011, 60:969-975. 10.1016/j.metabol.2010.09.006, 21040936.
38. Quintão EC, Cazita PM. Lipid transfer proteins: past, present and perspectives. Atherosclerosis 2010, 209:1-9. 10.1016/j.atherosclerosis.2009.08.002, 19733354.
39. Calabresi L, Baldassarre D, Simonelli S, Gomaraschi M, Amato M, Castelnuovo S, Frigerio B, Ravani A, Sansaro D, Kauhanen J, Rauramaa R, de Faire U, Hamsten A, Smit AJ, Mannarino E, Humphries SE, Giral P, Veglia F, Sirtori CR, Franceschini G, Tremoli E. Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk. J Lipid Res 2011, 52:1569-1574. 10.1194/jlr.P014977, 3137023, 21596929.
40. Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, Tybjaerg-Hansen A, Remaley AT. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem 2010, 56:1128-1137. 10.1373/clinchem.2009.139931, 20511449.
41. Riemens SC, van Tol A, Scheek LM, Dullaart RP. Plasma cholesteryl ester transfer and hepatic lipase activity are related to high-density lipoprotein cholesterol in association with insulin resistance in type 2 diabetic and non-diabetic subjects. Scand J Clin Lab Invest 2001, 61:1-9.
42. Xiao C, Watanabe T, Zhang Y, Trigatti B, Szeto L, Connelly PW, Marcovina S, Vaisar T, Heinecke JW, Lewis GF. Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Circ Res 2008, 103:159-166. 10.1161/CIRCRESAHA.108.178756, 18556574.
43. de Vries R, Borggreve SE, Dullaart RP. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin Lab 2003, 49:601-613.
44. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003, 36:421-429. 10.1016/S0009-9120(03)00078-X, 12951168.
45. Weingärtner O, Lütjohann D, Vanmierlo T, Müller S, Günther L, Herrmann W, Böhm M, Laufs U, Herrmann M. Markers of enhanced cholesterol absorption are a strong predictor for cardiovascular diseases in patients without diabetes mellitus. Chem Phys Lipids 2011, 164:451-456. 10.1016/j.chemphyslip.2011.03.008, 21501602.
46. Knopp RH, Retzlaff B, Fish B, Walden C, Wallick S, Anderson M, Aikawa K, Kahn SE. Effects of insulin resistance and obesity on lipoproteins and sensitivity to egg feeding. Arterioscler Thromb Vasc Biol 2003, 23:1437-1443. 10.1161/01.ATV.0000082461.77557.C7, 12816878.
47. Praveen EP, Kulshreshtha B, Khurana ML, Sahoo J, Gupta N, Kumar G, Ammini A, Knadgawat R. Low HDL-cholesterol among normal weight, normoglycemic offspring of individuals with type 2 diabetes mellitus. Hormones (Athens) 2011, 10:57-66.